ACLY and neoplasm: As we have stated, dichloroacetate, which inhibits PDK1 and restores drug sensitivity in paclitaxel-resistant lung cancer cells (A549), increases cytosolic citrate [28], while ACLY inhibition, which reduces tumor growth in various models, likely increases citrate level [87].